NDA 020610 · Valeant Pharms Intl
Colazal
Balsalazide Disodium · Oral
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jul 18, 2000
Approved uses
2
Original approval plus efficacy supplements
Registered trials
8
4 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2006 Supplement 16 · Efficacy · priority review Pediatric Clinical Pharmacology ReviewPediatric Medical ReviewLetter
- Jul 18, 2000 Original approval · Type 1 - New Molecular Entity NovelPediatric Written RequestPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- COLAZAL · BALSALAZIDE DISODIUM 750MG · CAPSULE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Balsalazide Disodium" as an intervention, any sponsor and status, largest first.
- Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01532648 · 510 participants · Start Jan 27, 2012 · Primary completion Oct 2, 2013
Drug: Budesonide MMX®; Placebo and 1 more · For: Ulcerative Colitis
Sites: Anaheim, California; Lakewood, California; San Diego, California · 114 sites in all
- Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis StudyPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00486031 · 443 participants · Start Oct 2006 · Primary completion Apr 2008
Drug: Balsalazide Disodium · For: Inflammatory Bowel Disease; Ulcerative Colitis
Sites: Birmingham, Alabama; Tempe, Arizona; Fayetteville, Arkansas · 95 sites in all
- Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative ColitisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00408174 · 400 participants (planned) · Start May 2006 · Primary completion Jul 2007
Drug: Balsalazide disodium · For: Inflammatory Bowel Disease; Ulcerative Colitis
Sites: Tempe, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 88 sites in all
- New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative ColitisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00269438 · 225 participants · Start Dec 2005 · Primary completion Mar 2007
Drug: 5 ASA, enemas, suppositories, corticosteroids · For: Ulcerative Colitis
Sites: Birmingham, Alabama; Mobile, Alabama; Little Rock, Arkansas · 66 sites in all
Mylan Pharmaceuticals IncIndustry
NCT00648531 · 80 participants · Start May 2004 · Primary completion May 2004
Drug: Balsalazide Disodium Capsules 750 mg; Colazal® Capsules 750 mg · For: Healthy
Sites: Fargo, North Dakota
Mylan Pharmaceuticals IncIndustry
NCT00649480 · 60 participants · Start Jan 2007 · Primary completion Feb 2007
Drug: BALSALAZIDE DISODIUM CAPSULES, 750 MG; COLAZAL® Capsules 750 mg · For: Healthy
Sites: Fargo, North Dakota
Roxane LaboratoriesIndustry
NCT00618202 · 52 participants · Start May 2005 · Primary completion Jun 2005
Drug: Balsalazide · For: Ulcerative Colitis
Sites: Houston, Texas
Roxane LaboratoriesIndustry
NCT00618228 · 52 participants · Start Jan 2004 · Primary completion Jan 2004
Drug: Balsalazide · For: Ulcerative Colitis
Sites: Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Colazal (Balsalazide Disodium)
2024 spending
$175K
Beneficiaries
12
58 claims
Per beneficiary
$14,599
$6.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $229,652 |
| 2021 | $246,664 |
| 2022 | $217,430 |
| 2023 | $196,716 |
| 2024 | $175,188 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.
Wiggins JB, Rajapakse R · Expert Opin Drug Metab Toxicol 2009 · Systematic Review
- Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ, Pruitt R, Gordon GL, et al. · Am J Gastroenterol 2009 · Comparative Study, Multicenter Study
Sponsor: Valeant Pharms Intl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.